Respiratory Syncytial Virus (RSV) Monoclonal Antibody for Infants (Nirsevimab)

Posted On: January 8, 2025

 

RSV is a common and very contagious virus that is a major cause of lower respiratory tract illness, especially in infants, young children, and older adults. In Canada, RSV causes annual outbreaks of respiratory tract disease, usually starting in the late fall and continuing through early spring. Limited does of nirsevimab, the long-acting RSV monoclonal antibody, will be made available for infants born after March 31, 2024, who primarily reside in eligible remote Vancouver Island Communities. Please see the MHO newsletter HERE for more information.